Varun Sharma · Founder, CEO & CTO
Building the systems medicine still needs
Varun Sharma is a Glasgow born British Indian pharmaceutical entrepreneur, the founder of NEUVIOR and the product architect behind PHARMORIS. His work connects medicines, technology and the operating discipline required to turn insight into action.

Origins
The operating education began behind a Glasgow shop counter.
In his published first person writing, Varun traces his earliest business education to his father’s corner shop. Stock had to move, cash had to be protected, customers had to trust you and a poor decision became visible quickly. The lesson was not glamour; it was responsibility.
That instinct stayed with him as his attention moved towards medicines, technology and complex institutions. He became interested in the point where good information stops being enough, where a decision needs an owner, a route through implementation and a result people can review.

Trust is operational
Customers remember whether the promise, product and action matched, not how sophisticated the explanation sounded.
Corner shop lessonCash and time expose truth
A useful system must respect the resources, constraints and people carrying the work every day.
Operating lessonThe detail compounds
Small decisions become a reputation, an operating model and eventually the institution you are building.
Founder lessonWhy he built NEUVIOR
You already have medicines evidence. The gap is what happens next.
Varun’s founder thesis is that modern medicines systems do not mainly suffer from a lack of analysis. They suffer when evidence, authority, delivery and review become disconnected across teams, inboxes and institutional boundaries.
He founded NEUVIOR to build the company around that gap. PHARMORIS is the first focused product: a human governed operating layer intended to help an authorised team move from a medicines signal to an ActionCase, a decision, coordinated work and a reviewable result.
Company direction
Set NEUVIOR’s commercial direction and connect the immediate product to a wider pharmaceutical thesis.
Founder and CEOProduct architecture
Lead the model connecting sources, CandidateSignals, human triage, ActionCases, delivery and ValueReview.
CTO and product architectPublic argument
Make the case for implementation discipline in medicines, pharmaceutical trade and complex technology systems.
Founder commentaryFounder led momentum
Use the opening wins to earn the next level of company.
NEUVIOR has been selected for non-dilutive support for defined project work. Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome. Varun has also developed a growing public voice across pharmaceutical, technology and business publications.
For Varun, the purpose of early support and attention is not to look larger than the business. It is to build the product, evidence, relationships and operating capability required for NEUVIOR to become the pharmaceutical institution it is designed to be.
Source linked support
Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.
Company public recordPHARMORIS
The first product through which the company can prove that medicines evidence becomes more useful when action remains governed and owned.
Product architecturePublished thinking
Commentary on neurodivergent founders, medicines implementation, pharmaceutical trade and the systems behind execution.
BusinessCloud to Pharmaceutical TechnologyEvidence index | Reviewed 20 August 2026
Read the record by evidence class, not by logo count.
This founder biography separates publisher-originated coverage, material written by or attributed to Varun, NEUVIOR-owned material and future ambition. Publication proves that a record exists. It does not by itself prove adoption, technical validation, regulatory authority, customer outcomes or endorsement.
No current newsroom entry is classified as fully independent reporting. Publisher records derived from announcements, roundups, syndication or partner material retain those labels. The distinction is deliberate and will change only when the source relationship changes.
- 01Independent coverage
- None currently verified as fully independent reporting. Publisher-hosted company records remain indexed by their actual source relationship rather than promoted as third-party validation.Current evidence state | None
- 02Authored commentary
- Bylined or attributed commentary includes medicines implementation, pharmaceutical quality, founder operating discipline and UK-India pharmaceutical trade. These records establish publication and authorship, not professional or regulatory credentials.External publisher | Founder voice
- 03Company material
- NEUVIOR Insights, governance proposals, product explanations and this biography are company-published material. They explain the operating thesis and evidence boundaries; they are not independent media coverage.Owned source | NEUVIOR
- 04Future ambition
- Longer-term pharmaceutical development, laboratories, manufacturing and international institution-building remain direction to be earned through evidence, rights, capital, capability and approvals. They are not present operating claims.Forward thesis | Not current capability
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed analysis. Pharmaphorum. Approval is not access: Pilots' real test is implementation. 18 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- Founder commentary. BusinessCloud. Why neurodivergent founders can excel at building complex systems. 18 March 2026.
- Founder commentary. Startups Magazine. What my dad's corner shop taught me. 6 May 2026.
- Founder viewpoint. Pharmaceutical Technology. Why the India UK trade deal now needs a five gate implementation ledger. 28 July 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- NEUVIOR analysis. NEUVIOR Insights. From medicines intelligence to medicines development: the founder thesis connecting NEUVIOR and VARUNÉ Labs. 1 August 2026.
Classified public record
VARUN SHARMA · PUBLISHED THINKING
See how Varun Sharma thinks when the idea is only the start.
From a Glasgow corner shop to pharmaceutical trade and medicines implementation, the common thread is execution: who owns the next decision, what evidence matters and what makes the work move.
AI and Accountability: When Does a Suggestion Become a Decision?
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
Hear Varun on accountable AIApproval is not access: Pilots' real test is implementation
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
Read Varun on medicines implementationFive questions to test whether an AI stack is truly under your control
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
Read Varun's five tests for AI control
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
Make the next step useful
Bring the problem that needs a clearer decision.
Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.
